Trial Profile
A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- 26 Jan 2018 Results presented in a XBiotech Media Release.
- 26 Jan 2018 According to an XBiotech media release, retrospective analysis from data of this study will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference.
- 19 Jan 2018 According to an XBiotech media release, results from an open label extension phase of this study will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference.